NCLAT Sets Aside Insolvency, Imposes ?10L Costs Following Recusal over Attempt to Influence Member || J&K&L HC: Sec 195 CrPC Bars Cognizance Without Public Servant's Complaint, Not FIR or Investigation || Allahabad HC: Preliminary Issues Barred if Raised 18 Years After Issues Were Framed in a Suit || Guj HC: No Prior Hearing Needed to Dismiss Cop After Corruption Conviction under Article 311(2)(A) || Madras HC: Senior Citizens Act Applies Only To Post-2007 Property Transfers, Not Retrospective || Supreme Court: Private Insurer Not Liable For Accident by Vehicle under State Requisition || SC: Reserved Candidates Can Claim General Seats on Merit with Relaxation if Rules Allow || SC: No Vested Right to Appointment For Next Candidate if Selected One Doesn't Join || Supreme Court Restores Arbitral Award, Rules State Cannot Be Judge in its Own Dispute Case || Delhi HC: Girl Being Friendly on Valentine’s Day Does Not Justify Forced Sexual Activity under POCSO

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :